Article

Predicting Individual Responses in Phase I Oncology Trials Using Routinely Collected Clinical Biomarkers

2024-10-16

Abstract excerpt

<title>Abstract</title> <p>Information which may support an individual’s participation in a cancer phase I trial, such as their response to prior therapies, other medical conditions they may have, features in their tumor genomic profile, etc., should be considered to avoid negative consequences of participating in the trial. However, knowing which pieces of information are relevant is crucial. We built predictive...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: aed12a58-0623-5159-b490-a1ddd6f57a87
DOI: 10.21203/rs.3.rs-4910461/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Predicting Individual Responses in Phase I Oncology Trials Using Routinely Collected Clinical BiomarkersDOI 10.21203/rs.3.rs-4910461/v1Read

Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials.Semantic proximity Read

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptomeSemantic proximity Read

Predict progression free survival and overall survival using objective response rate for anti - PD1 / PDL1 therapy developmentSemantic proximity Read

Prospective–Retrospective Biomarker Analysis for Regulatory Consideration: white Paper from the Industry Pharmacogenomics Working GroupSemantic proximity Read

AI-Driven Predictive Biomarker Discovery with Contrastive Learning to Improve Clinical Trial OutcomesSemantic proximity Read

Incorporating Real-World Clinico-Genomic Insights to Inform Diversity Enrollment Targets in Oncology TrialsSemantic proximity Read

Biostatistic tools in pharmacogenomics--advances, challenges, potential.Semantic proximity Read

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.Semantic proximity Read

Clinical Utility of the EpiSwitch CiRT Test to Guide Immunotherapy Across Solid Tumors: Interim Results from the PROWES StudySemantic proximity Read

A Reproducible Health Informatics Pipeline for Simulating and Integrating Early-Phase Oncology Clinical, Biomarker, and Pharmacokinetic Data for Exploratory Decision-Support AnalyticsSemantic proximity Read

Examining the Feasibility and Functionality of Common Analysis Methods for Longitudinal Data with Binary OutcomesSemantic proximity Read

Statistical and practical considerations for clinical evaluation of predictive biomarkers.Semantic proximity Read